Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa
Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa
Ocugen 在 3 期试验设计的关键方面获得了 FDA 的同意，该试验设计旨在评估 OCU400 在患有 Rho 和其他与色素性视网膜炎相关的基因突变患者中的安全性和有效性
Ocugen Received Alignment From FDA On Key Aspects Of The Phase 3 Trial Design To Assess The Safety And Efficacy Of OCU400 In Patients With Rho And Other Gene Mutations Associated With Retinitis Pigmentosa
Ocugen 在 3 期试验设计的关键方面获得了 FDA 的同意，该试验设计旨在评估 OCU400 在患有 Rho 和其他与色素性视网膜炎相关的基因突变患者中的安全性和有效性